Abstract
Some of the key steps in cancer metastasis are the migration and invasion of tumor cells; these processes require rearrangement of the cytoskeleton. Actin filaments, microtubules, and intermediate filaments involved in the formation of cytoskeletal structures, such as stress fibers and pseudopodia, promote the invasion and metastasis of tumor cells. Therefore, it is important to explore the mechanisms underlying cytoskeletal regulation. The ras homolog family (Rho) and Rho-associated coiled-coil containing protein serine/threonine kinase (ROCK) signaling pathway is involved in the regulation of the cytoskeleton. Moreover, long noncoding RNAs (lncRNAs) have essential roles in tumor migration and guide gene regulation during cancer progression. LncRNAs can regulate the cytoskeleton directly or may influence the cytoskeleton via Rho/ROCK signaling during tumor migration. In this review, we focus on the regulatory association between lncRNAs and the cytoskeleton and discuss the pathways and mechanisms involved in the regulation of cancer metastasis.
The Mechanical Challenge of Metastasis
Metastasis—the spread of cancer from a primary tumor to distant organs—is responsible for the vast majority of cancer-related deaths. For a tumor cell to move, it must physically reorganize its internal scaffold, the cytoskeleton, which is comprised of actin filaments, microtubules, and intermediate filaments. While the protein-based signaling pathways that govern this movement, such as the Rho/ROCK pathway, are well-mapped, the regulatory layer above them is only recently coming into focus.
Specifically, the human genome is 75% transcribed into RNA, yet only ~2% codes for proteins. This review addresses the gap in our understanding of how the remaining "noncoding" portion, specifically long noncoding RNAs (lncRNAs), orchestrates the mechanical changes required for a cell to become invasive.
Synthesizing the Noncoding Landscape
As a comprehensive literature review, this paper synthesizes findings from 114 cited studies to categorize lncRNAs based on their mechanical targets. The authors mapped out two primary modes of action:
- Direct Regulation: lncRNAs physically binding to cytoskeletal proteins (e.g., vimentin or actin-bundling proteins).
- Indirect Regulation: lncRNAs acting as "sponges" for microRNAs (competitive endogenous RNA or ceRNA mechanism) or signaling modulators that influence the Rho/ROCK pathway.
The Mechanical Switch: Direct Cytoskeletal Regulation
The paper highlights that lncRNAs are active mechanical regulators rather than passive bystanders. For instance, the lncRNA Dreh acts as a tumor suppressor by binding to intermediate filaments, preventing the structural changes needed for metastasis. Conversely, several lncRNAs, including HOTAIR, CCAT2, and LOC344887, are identified as regulators of vimentin, a key marker of the epithelial-mesenchymal transition (EMT) that allows cells to detach and migrate.
Other direct hits include PTCSC2, which binds to MYH9 (myosin-9) to regulate the actin scaffold, and GAS5, which induces cofilin inactivation. This inactivation slows down the "treadmilling" of actin filaments, thereby inhibiting glioma cell movement.
Hijacking the Rho/ROCK Signaling Engine
The Rho family of GTPases (RhoA, Rac1, Cdc42) and their effector, ROCK, serve as the "engines" of cell movement. LncRNAs often act as upstream controllers of this engine, either accelerating or braking the formation of stress fibers and lamellipodia.
A recurring theme is the competitive endogenous RNA (ceRNA) network, or "sponge" effect. lncRNAs can bind to microRNAs, preventing them from silencing their target mRNAs. A prominent example is MALAT1, which sponges miR-1 to increase the expression of Cdc42, promoting cell migration in breast cancer. Similarly, AFAP1-AS1 stimulates stress fiber formation via RhoA/Rac2 signaling in nasopharyngeal carcinoma.
Clinical Implications and Future Frontiers
The dysregulation of these lncRNAs consistently correlates with poor prognosis and increased distant metastasis in patients. For example, high levels of LINC00152 or UCA1 are linked to aggressive disease progression.
Despite these insights, several hurdles remain:
- Mechanistic Gaps: The exact molecular "handshake" between many lncRNAs and the protein machinery is still unknown.
- Technological Needs: More sophisticated technologies are required to measure real-time cytoskeletal changes and lncRNA interactions within 3D tumor environments.
- Therapeutic Delivery: Effectively delivering RNA-based therapies to tumor sites without degradation remains a significant barrier to clinical application.
The review concludes that while the "players" have been identified, future research must focus on the "playbook"—the precise spatial and temporal coordination of these molecules during the metastatic journey.
Summary updated